DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xg2c7h/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H2 2013" report to their offering.

“Smoking Cessation - Pipeline Review, H2 2013”

'Smoking Cessation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Smoking Cessation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smoking Cessation.

Scope

• A snapshot of the global therapeutic scenario for Smoking Cessation.
• A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Smoking Cessation pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Companies Mentioned

Aradigm Corporation

GlaxoSmithKline plc

Laboratoires Pierre Fabre SA

Pfizer Inc.

Targacept, Inc.

CBio Limited

Marinus Pharmaceuticals, Inc.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Royalty Pharma

Selecta Biosciences, Inc.

Embera NeuroTherapeutics, Inc.

Celtic Pharmaceutical Holdings L.P.

NAL Pharmaceuticals Ltd.

BIOPROJET SCR

For more information visit http://www.researchandmarkets.com/research/xg2c7h/smoking_cessation

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.